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two different batches of monoclonal anti-A, anti-B, anti-A,BIntroduction
The ABO blood group system plays an important role in trans-
fusion and transplantation practices. Correct identiﬁcation of
the blood group of an individual is of paramount importance
as minor errors can lead to fatal transfusion reactions. Weak
expression of A, B and H antigens on the red cell surface can be
inherited or acquired. They are probably the least frequently
encountered and pose a challenge in the routine immunohe-
matology practice.1 Such antigenic changes in hematological
malignancies most commonly involve the ABO blood group
system.2 The strength of agglutination with anti-B, anti-A,B,
and anti-H serum, presence or absence of ABO isoagglutinins
in the serum, adsorption-elution studies and the presence or
absence of A, B and H substance in saliva along with pedi-
gree analysis help to characterize the weaker variants of A
and B serologically. Possible phenotypic subgroups include A3,
Aend, Ax, Am,  Ay, and Ael. Subgroups of B are very rare, less
frequent than those of A and are classiﬁed as B3, BX, Bm
and Bel in decreasing order of the amount of the B antigen
(Table 1).
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open  access article under the CC BY-NC-ND license (http://creativecomHere we would like to share a case of the B3 blood group
in a patient who was recently diagnosed with acute myeloid
leukemia (AML) M3 with no known comorbid illness. To the
best of our knowledge, this is the ﬁrst report from India.
Case  report
A 50-year-old gentleman was admitted to our tertiary care
center with a one-month history of generalized weakness.
A complete blood count revealed Hb: 7.9 g/dL, platelet count:
20,000/L and total WBC  count: 148,300/L. Peripheral smear
examination revealed 90% atypical cells suggestive of acute
leukemia and ﬂow cytometric immunophenotyping of the
peripheral blood sample conﬁrmed AML-M3.
Blood grouping was done using the standard tube
technique and column agglutination technology (Ortho Diag-
nostics, USA). Forward/cell grouping was performed usingda Hospital, Malakpet, 500036 Hyderabad, India.
(Eryclone, Tulip diagnostics, Goa, India), anti-D antisera (Rho-
ﬁnal, Tulip diagnostics, Goa, India) and anti-H lectin (Erybank,
Tulip diagnostics, Goa, India) reagents and reverse/serum
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
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Table 1 – Serological characteristics of B phenotypes.1
Phenotypes Anti-A Anti-B Anti-A,B Anti-H Antibodies in serum Substances in saliva
B 0 4+ 4+ 2+ Anti A B, H
B3 0 2+mf 2+mf 3+ Anti A B, H
Bx 0 Wk 3+ Anti A, weak anti B H
Bm 0 0/wk 0/wk 3+ Anti A B, H
Bel 0 0 0 3+ Anti A, sometimes weak anti B H
0: no agglutination; mf: mixed ﬁeld agglutination; wk: weak agglutination.
Table 2 – Serological evaluation of the ABO discrepancy (using tube technique).
Anti-A Anti-B Anti-D Anti-A,B Anti-H A1 cell B cell 0 cell Autocontrol
0 2+/mf
3+/mf at 4 ◦C
incubation for 1 h
3+ 2+/mf
3+/mf at 4 ◦C
incubation for 1 h
3+ 4+ 0 0 0
0: no agglutination; mf: mixed ﬁeld agglutination.
Figure 1 – Results of forward blood grouping by column






7 determine whether glycosyltransferase will use UDP-N-gglutination with anti-B.
rouping was done using in-house prepared pooled group A1,
 and O reagent red cells. The blood group was interpreted
ased on the agglutination in forward and reverse grouping
Table 2).Forward grouping using the tube technique showed mixed
ﬁeld appearance with anti-B and anti-A,B antisera. Incubation
of the forward grouping tubes at 4 ◦C showed 3+/mf agglutina-
tion reaction with anti-B and anti-A,B antisera while reverse
grouping results remained the same. Repeat blood grouping
was carried out by the tube technique with another fresh sam-
ple and it was found to be no different to the previous results.
Results were conﬁrmed by column agglutination technology
(ORTHO BioVueTM, Ortho Clinical Diagnostics, USA) (Figure 1).
His blood group was B Rh D positive as per his previous records.
The adsorption and elution test was performed as
described in the American Association of Blood Banks (AABB)
technical manual.3 Adsorption of patient red cells was done
at 4 ◦C with human polyclonal anti-B from group A individ-
uals. Heat elution was performed at 56 ◦C for 10 min. Eluate
and ﬁnal wash supernatant were tested with three unpooled
A, B and O blood group reagent red cell samples. Eluate reacted
only with group B cells whereas ﬁnal wash supernatant was
non-reactive with A, B or O cells.
His saliva secretor status was determined using the hemag-
glutination inhibition test as described in the AABB technical
manual.4 B and H antigens were absent in his saliva and so
he was a non-secretor. According to the standard terminology
of ABO subgroups, his blood grouping and Rh typing was B3
Rh D positive. Since he had a low platelet count, single donor
apheresis platelets of group B were transfused; the procedure
was uneventful. ABO discrepancy in his blood grouping was
weak B antigen expression with mixed ﬁeld appearance. This
is an example of an acquired variant of B (secondary to the
underlying myeloid leukemia).
Discussion
The ABO gene is located on chromosome 9 and consists
of seven exons with the majority of the coding sequences
in exon 6 and 7. The amino acid substitutions within exonacetyl-d-galactosamine (A transferase) or UDP-d-galactose (B
transferase) donor sugars to synthesize A or B antigens,




1266  rev bras hematol hem
in the inactive enzyme is characteristic of O alleles. Single
nucleotide substitutions in exon 6 and 7 give rise to different
ABO alleles.1
In our patient, the characteristic ﬁnding was weakened
B expression with mixed ﬁeld agglutination mimicking the
B3 phenotype. Diminished expression of ABH antigens can
occur with variant ABO alleles and in hematological disorders
such as leukemia, myeloproliferative disorders, myelodysplas-
tic syndrome and in some cases of Hodgkin’s lymphoma. It has
also been found in healthy elderly adults, pregnant females
and neonates.2,5,6 Myeloid neoplasms have been reported to
be more  frequently associated with ABH antigenic alterations
than lymphoid malignancies. AML  associated with a weak A
antigen was ﬁrst elucidated by Van Loghem et al. in 1957 in a
patient who had a previously normal A antigen on red cells.
Flow cytometric analysis has shown decreased expression of
ABH blood group antigens in patients with myeloid leukemia.
Diminished expression of A and/or B antigens could be due
to a blockage of the conversion of H substance to A and/or B
substances or decreased synthesis of H antigens.7 Since the
ABO locus encoding A and B transferases is in the 9q34 region,
the chromosomal translocation (9 and 22) observed in patients
with myeloid leukemia (both chronic myeloid leukemia and
rarely AML) has also been linked to ABH red cell antigenic
changes in these patients.2
Apart from the A3 and B3 alleles, mixed ﬁeld reactiv-
ity can be encountered in recent transfusion, hematopoietic
(bone marrow and stem cell) transplantation, fetomater-
nal hemorrhage, and twin or dispermic chimerism.8 Our
patient had no such history. Mixed ﬁeld reactions can also be
observed in hematological malignancies (particularly myeloid
leukemia) where a varying proportion of red blood cells do not
agglutinate.2,7 Weakened expression of the A antigen on red
cells mimicking the A3 phenotype was reported by Salmon
et al. in patients with leukemia.5
The B3 phenotype is characterized by mixed ﬁeld hemag-
glutination with anti-B and anti-A,B serum, absence of anti-B
antigen in the serum and normal B antigen in the saliva
(secretors). The B3 subgroup is the most frequent weak B
phenotype.1 The B3 phenotype occurs with a frequency of
1/900 B and 1/1800 A1B in the Chinese population9 and with
a frequency of 1:116,667 in French donors.10 Reports from
India show the frequency of the weak B phenotype to be
1:86,687 among the donors of north India10 and 1:24,000 from
Bombay.11 However the exact frequency is not known. Infre-
quent reporting of these ﬁndings could be due to lack of
knowledge and the complex classiﬁcation of subgroups.
B3 alleles arise due to amino acid substitutions (due to
nucleotide substitutions in exon 7) in the glycosyltransferase
B enzyme although a splice site mutation in exon 3 has been
reported in only one B3 allele.5 There may be qualitative
(difference in the ability to bind the antibody) as well as quan-
titative (number of antigens on red blood cells) differences in
the B antigen of B3 red cells from normal B cells.9 It is safe to
transfuse O group red cells in a patient with red blood cells
expressing a variant ABO.12
Weakening of ABH antigen expression suggests a pre-
leukemic state as they appear even before recognizing the
1 2 0 1 6;3  8(3):264–266
malignancy. Follow-up of these patients will be helpful as the
amount of antigens returns to normal on red blood cells with
complete remission.5 Correct ABO grouping is required not
only for ensuring a safe transfusion to patients but also for
understanding the true epidemiology of weak subgroups in a
given population.
Conclusions
Weak subgroups of the ABO blood group system are hardly
reported in the day-to-day practice. Such ABO discrepan-
cies are resolved by extended incubation of forward grouping
tubes at 4 ◦C, saliva secretor studies, adsorption-elution meth-
ods and pedigree analysis. Early recognition of the loss of
ABH antigens is extremely important because it may indicate
underlying sinistrous pre-leukemic states. Follow-up of the
patients is necessary as these antigenic changes mirror the
course of leukemia. In patients with hematological malignan-
cies, correct ABO blood grouping is important as they require
multiple transfusions and often undergo hematopoietic stem
cell transplantation.
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